Passage Bio, has the mission to provide life-transforming gene therapies for patients with rare, monogenic CNS diseases that replace their suffering with boundless possibility, all while building lasting relationships with the communities it serves. Based in Philadelphia, PA, the company has established a strategic collaboration and licensing agreement with the renowned University of Pennsylvania's Gene Therapy Program to conduct its discovery and IND-enabling preclinical work. This provides the team with enhanced access to a broad portfolio of gene therapy candidates and future gene therapy innovations that Passage Bio then pairs with its deep clinical, regulatory, manufacturing and commercial expertise to rapidly advance its robust pipeline of optimized gene therapies into clinical testing. As the company works with speed and tenacity, Passage Bio is always mindful of patients who may be able to benefit from its therapies.